Carvedilol, probably the β‐blocker of choice for everyone with cirrhosis and portal hypertension: But not so fast!-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Carvedilol, probably the β‐blocker of choice for everyone with cirrhosis and portal hypertension: But not so fast!

Published:2023-05-11 Issue:6 Volume:43 Page:1154-1156
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver International

Author:

Villanueva Càndid¹²^ORCID,Tripathi Dhiraj³⁴⁵

Affiliation:

1. Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau) Universitat Autònoma de Barcelona Barcelona Spain

2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Spain

3. University Hospitals Birmingham NHS Foundation Trust Birmingham UK

4. Institute of Immunology and Immunotherapy University of Birmingham Birmingham UK

5. Department of Hepatology Royal Infirmary of Edinburgh Edinburgh UK

Funder

Instituto de Salud Carlos III

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.15582

Reference20 articles.

1. Baveno VII – Renewing consensus in portal hypertension

2. Beta-blockers in portal hypertension: new developments and controversies

3. Carvedilol as the new non‐selective beta‐blocker of choice in patients with cirrhosis and portal hypertension

4. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments

5. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP